The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV.

被引：11
|
作者：
Wang-Gillam, Andrea
Chen, Li-Tzong
Li, Chung-Pin
Bodoky, Gyorgy
Dean, Andrew
Lee, Kyung-Hun
Cunningham, David
Hubner, Richard
Braiteh, Fadi S.
Pipas, J. Marc
Belanger, Bruce
de Jong, Floris A.
Mody, Purvi D.
Von Hoff, Daniel D.
Siveke, Jens T.
机构：
[1] Washington Univ, Sch Med St Louis, St Louis, MO USA
[2] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan
[3] Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Szent Laszlo Teaching Hosp, Budapest, Hungary
[5] St John God Hosp, Subiaco, WA, Australia
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Royal Marsden Hosp, Sutton, Surrey, England
[8] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[9] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[10] Merrimack Pharmaceut Inc, Cambridge, MA USA
[11] Shire GmbH, Zug, Switzerland
[12] Translat Genom Res Inst TGen, Phoenix, AZ USA
[13] HonorHealth, Phoenix, AZ USA
[14] Univ Hosp, West German Canc Ctr, Essen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15795
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15795
引用
收藏
页数：6
相关论文
共 36 条
  • [1] Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone
    Hubner, R. A.
    Chen, L-T.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Lee, K-H.
    Cunningham, D.
    Siveke, J. T.
    Braiteh, F. S.
    de Jong, F. A.
    Belanger, B.
    Walls, R.
    Mody, P. D.
    von Hoff, D. D.
    Wang-Gillam, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
    Chen, L-T.
    Macarulla, T. M.
    Belanger, B.
    Mirakhur, B.
    de Jong, F. A.
    Siveke, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G. S.
    Macarulla, T.
    Lee, K-H.
    Cunningham, D.
    Blanc, J-F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    Belanger, B.
    Bayever, E.
    de Jong, F.
    von Hoff, D. D.
    Siveke, J. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
    Ioka, T.
    Nakamori, S.
    Sugimori, K.
    Kanai, M.
    Ikeda, M.
    Ozaka, M.
    Furukawa, M.
    Okusaka, T.
    Kawabe, K.
    Furuse, J.
    Komatsu, Y.
    Sato, A.
    Shimizu, S.
    Chugh, P.
    Tang, R.
    Ueno, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Lee, Kyung-Hun
    Cunningham, David
    Hubner, Richard
    Siveke, Jens T.
    Braiteh, Fadi S.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris
    Mody, Purvi D.
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [7] Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Shan, Yang-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L. -T.
    Siveke, J.
    Wang-Gillam, A.
    Hubner, R.
    Pant, S.
    Dragovich, T.
    Chung, V.
    Chang, D.
    Ross, P.
    Cooray, P.
    Tebbutt, N.
    Franke, F.
    Belanger, B.
    Dhindsa, N.
    de Jong, F.
    Mamlouk, K.
    Von Hoff, D.
    ANNALS OF ONCOLOGY, 2016, 27 : 110 - 110
  • [9] Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.
    Pelzer, Uwe
    Blanc, Jean-Frederic
    Melisi, Davide
    Cubillo, Antonio
    Von Hoff, Daniel D.
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Siveke, Jens T.
    Wan, Yin
    Solem, Caitlyn T.
    Botteman, Marc
    Yang, Yoojung
    de Jong, Floris
    Hubner, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
1234